Petersen, Jana
Garbe, Claudia
Wolf, Sandra
Stephan, Brigitte
Augustin, Matthias
Hagenström, Kristina
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 24 August 2021
Accepted: 7 January 2022
First Online: 21 March 2022
Declarations
:
: M. Augustin has served as consultant and/or paid speaker for and/or has received research grants and/or honoraries for consulting and/or scientific lectures for and/or got travel expenses reimbursed and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis including Abbott/AbbVie, ALK Scherax, Almirall, Amgen, Beiersdorf, Biogen Idec, BMS, Boehringer Ingelheim, Celgene, Centocor, Dermira, Eli Lilly, Forward Pharma, Fresenius, Galderma, GSK, Hexal, Incyte, Janssen-Cilag, LEO Pharma, Lilly, Medac, Menlo, Merck, MSD, Mylon, Novartis, Pfizer, Regeneron, Sandoz, Sanofi-Aventis, Stallergenes, Stiefel, Teva, TK, Trevi, UCB and Xenoport. J. Petersen, C. Garbe, S. Wolf, B. Stephan and K. Hagenström declare that they have no competing interests.
: The study was conducted according to the Declaration of Helsinki. We considered the criteria of the national good practice guidelines. According to the Good Practice of Secondary Data Analysis, a national guideline for the use of administrative databases, no approval of an ethical committee was required.